Wednesday, 21 October 2026European Markets

Palantir's AI Momentum Meets a Sour Defence Tape: What It Means for a European Reader

Analysts turned more bullish on Palantir in mid-October 2026 while J.P. Morgan's lead defence analyst downgraded Leidos and warned of a weak sector. The dossier holds little European regulatory material, so we say so, and set out what was said, by whom, and how reliable the sources are.

LM Salvado
LM Salvado

October 21, 2026

Palantir's AI Momentum Meets a Sour Defence Tape: What It Means for a European Reader
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

The short version, and an honest caveat

Two things happened in the same fortnight. Several analysts became more positive on Palantir, the US software and AI company that serves government and commercial customers.1 Meanwhile J.P. Morgan's lead aerospace and defence analyst described a challenging earnings season for the sector and downgraded Leidos, a US defence contractor.2 The two stories pull in opposite directions, and they show how differently the market treats an AI software platform and a defence contractor.

For a European business reader there is a limit to what we can say. Our verified material contains no EU regulation, no European company results and no European market data on this story. We will not invent a European angle. The one thread that touches European concerns is sovereign AI, covered below. We flag where the evidence stops.

What happened to Palantir's shares

On Friday 16 October 2026 Palantir fell more than 7% to close at $186.03, a drop of $14.47. It was the fifth lower close in a row, following a 52-week high of $212.94 set earlier that week. The fall came during a broader technology selloff that weighed on the Nasdaq-100.1 If you hold a global or US technology index fund, you may own some Palantir indirectly. The dossier does not give its weighting in any index, so we cannot say how much.

The bullish calls arrived in the same stretch. Bernard Zambonin stays constructive on Palantir. He points to customer expansion and net dollar retention (how much more existing customers spend year on year) as central to the bull case. He also acknowledges that the elevated forward valuation makes continued execution essential.1 In plain terms, the shares are priced for things to keep going well, and the analyst says so.

Ryan Canady upgraded Palantir to Buy. He concluded that customer-built AI applications can remain complementary to Palantir's platforms rather than displace its core offering.1 That addresses a real investor worry, that customers might build their own tools instead of paying for Palantir's. It is a judgement about the future, not a measured result.

The partnership run

Palantir's announcements in the same days point the same way, towards ecosystem deals:

  • On 14 October, Customers Bank announced a collaboration with Palantir to develop an AI-oriented banking operating model. Its own forward-looking statements highlight implementation risks, reliability concerns and contractual flexibility.3
  • On 14 October, Surf Air Mobility signed Flying Zebra as its fifth commercial OperatorOS customer, with software powered by Palantir. Surf Air receives a percentage of revenue from trips managed through the platform.4
  • On 13 October, Ondas and Palantir announced Regna AI, a standalone private company to help governments, businesses and institutions develop and deploy AI models in sovereign environments. Palantir is expected to provide model-training infrastructure and engineering.5

The Customers Bank wording is a useful reminder. A partnership announcement is not revenue, and the bank itself lists reliability and implementation risk as things that could go wrong.3

Regna AI is the closest this story gets to European concerns. Keeping AI models inside a government's or institution's own controlled environment is a theme European buyers care about. However, the dossier does not say that any European customer is involved, and we make no claim that one is.5

The defence side: a different mood

In an 8 October research report, J.P. Morgan's lead aerospace and defence analyst, Seth M. Seifman, said most companies should deliver solid quarterly results and express confidence in underlying demand. But encouraging earnings may not be enough to reverse the sector's recent stock-market weakness.2 The report cites slowing airline traffic growth, uncertainty over US military spending and lingering supply-chain constraints as weights on investor sentiment.2

On Leidos, Seifman's view is that its relatively low valuation is insufficient to justify an Overweight rating when other aerospace and defence stocks also offer substantial potential returns.2 That is a relative call. It says other defence shares look at least as attractive, not that Leidos is a bad business. Seifman also expects Howmet's 2026 earnings estimates to rise, with management confident about growth in aerospace and industrial gas turbines.2 So the sour mood is not uniform across the sector.

Political timing adds to the uncertainty. The US congressional midterm elections on 3 November 2026 could change congressional control and constrain military spending growth. Some uncertainty may dissipate after that date.6 Our entity data also records BigBear.ai as a competitor of Leidos.7 We have no further data on that relationship, so we draw no conclusion from it.

Is this really a contrast?

The framing of AI momentum against defence gloom is neat, and we treat it with caution. Palantir sells to both government and commercial customers,1 so it is not simply on the other side of the defence trade. The dossier gives no Palantir revenue split, no defence exposure figure and no Palantir financial statement. Without those we cannot say how much a weak defence tape matters for Palantir. This is an observation about timing and mood, not a measured link.

The Palantir selloff also complicates the bullish story. The shares fell about 7% in a day on a broad tech decline, after analysts had turned more positive.1 Good commentary and a rising share price are different things.

How far to trust the sources

Every claim above comes from NewsEOD articles. Our own measurement of that source puts its reliability at 58% of 927 checked claims holding up.1,2 That is a meaningful miss rate, and the reason we attribute each view to a named analyst rather than stating it as fact. The analyst quotes are what the articles report those analysts as saying. We have not seen the underlying research notes.

The verified, SEC-filing-backed figures in our dossier concern Goldman Sachs, not Palantir or Leidos, so we have not used them here. Nothing in this piece is a checked Palantir financial figure.

What to watch

  • 3 November: the US midterm elections. J.P. Morgan flagged them as a source of defence budget uncertainty that may ease afterwards.6
  • Palantir's execution: Zambonin ties the bull case to customer expansion and net dollar retention.1 Any updated figures on these would test the case directly.
  • Regna AI details: who the customers are, and whether any are European, would show whether the sovereign-AI idea reaches this audience.5
  • Defence earnings: whether solid results actually lift the sector, as Seifman doubts they will.2

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score12 source documents12 with a live linkVerifiability: Strong
  1. [1]News articleYahoo Finance· July 11, 2026
    173-year-old denim giant sees one fashion trend surge 70%
  2. [2]News articleNasdaq· July 3, 2026
    Bull of the Day: Bloom Energy (BE)
  3. [3]News articleSeeking Alpha· July 28, 2026
    D-Wave Quantum dips 10%, moderating previous day's rally
  4. [4]News articleSeeking Alpha· June 24, 2026
    KB Home outlines Q3 2026 housing revenue $1.2B-$1.35B with gross margin 16%-16.6%
  5. [5]News articleSeeking Alpha· October 8, 2026
    Leidos downgraded by J.P. Morgan as defense stocks face rocky earnings season
  6. [6]News articleMotley Fool
    NuScale Power Stock Will Spike 23.7% Over the Next 11 Months According to This Wall Street Analyst
  7. [7]News articleSeeking Alpha· October 16, 2026
    Palantir Technologies declines 7% amid broader tech selloff
  8. [8]News articleMotley Fool
    Why Iovance Biotherapeutics Stock Was on Fire Today
  9. [9]News articleMotley Fool
    Why Wendy's Stock Withered on Wednesday
  10. [10]News articleSeeking Alpha· September 30, 2026
    FactSet expects 5% to 6.5% organic ASV growth in FY '27 while pointing to 25 to 75 bps margin improvement
  11. [11]News articleSeeking Alpha· July 29, 2026
    Landstar outlines July truck revenue per load up about 26% year-over-year while shifting to Q3 commentary over guidance
  12. [12]News articleSeeking Alpha· October 6, 2026
    RPM projects fiscal 2027 mid-single-digit sales and adjusted EBITDA growth as Q2 raw material inflation rises to 9%–11%
LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Crunch: Late-Stage Readouts and Regulatory Milestones Converge on the Ivonescimab PDUFA Date
October 2026 is dense with clinical and regulatory news. Phase 3 trials hit primary endpoints (ALOFT-IPF, RESTORE-3), long-term data came out (MIUDELLA at 6 years, QUILT-3.032), and the FDA accepted Roche's vamikibart BLA. Scholar Rock resubmitted its apitegromab MAA to the EMA. The next catalysts are ESMO 2026 (Oct 23) and the Nov 14 FDA PDUFA date for ivonescimab, followed by Maritime-1 primary completion in January 2027. The speculative QAIAx items (QIII pilot, microcities patent) are a weak, tangential thread with little financial substance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,406 source documents archived
Query this data → isubstrate.com